VCEL Profile
Vericel Corporation, a leading commercial-stage biopharmaceutical company, specializes in the research, development, manufacturing, and distribution of advanced cellular therapies tailored for the sports medicine and severe burn care markets in the United States. The company focuses on autologous cell therapy products, which are derived from the patient’s own cells to ensure compatibility and efficacy. Key products include MACI, an autologous cellularized scaffold designed for the repair of symptomatic, full-thickness cartilage defects in the knee. MACI utilizes a patient's own cells to regenerate cartilage and alleviate pain, making it a critical option for individuals suffering from significant knee damage.
Another major product is Epicel, a permanent skin replacement device intended for the treatment of deep-dermal or full-thickness burns. Epicel is used for both adult and pediatric patients, offering a solution for severe burns that require substantial skin regeneration. This product underscores Vericel's commitment to addressing complex skin injuries with innovative cellular therapies.
Vericel is also advancing its preapproval-stage product, NexoBrid, which is a biological orphan drug in the registration phase. NexoBrid is designed for the removal of escharâ€thick, dead tissueâ€in adults with deep partial-thickness or full-thickness thermal burns. This product represents a significant advancement in burn care, aiming to improve the treatment process and outcomes for patients with severe burn injuries.
Founded as Aastrom Biosciences, Inc. in 1989 and rebranded to Vericel Corporation, the company is headquartered in Cambridge, Massachusetts. With a focus on cutting-edge cellular therapies and a robust pipeline of products, Vericel continues to drive innovation in the biopharmaceutical industry, enhancing treatment options for patients with severe orthopedic and burn conditions.
|
